Retatrutid 40mg we yu de yuz

▎ Ritatrutid Strukchɔ

Sos: PubChem

Sikεns: YA⊃1;QGTFTSDYSI-L⊃2;LDKK4AQA⊃1;AFIEYLLEGGPSSGAPPPS⊃3; Mɔlikul Fɔmula: C 221H 342N 46O68 Molikul Weyt: 4731 g/mol CAS Nɔmba: 2381089-83-2 PubChem CID: 171390338, ɛn di ɔda wan dɛn Sinonim dɛn:LY3437943

▎ Risach we dɛn kɔl Retatrutid

Wetin na di risach bakgrɔn fɔ Retatrutid?

Di bɔku bɔku pipul dɛn we fat ɛn tayp 2 dayabitis na di wɔl de kɔntinyu fɔ bɔku, ɛn dis de mek pipul dɛn gɛt bɔku prɔblɛm wit dɛn wɛlbɔdi biznɛs. Di drɔgs dɛn we de naw we gɛt wan ɔ tu target gɛt limiteshɔn pan ɛfifikɛshɔn ɛn sef. bays pan di tiori fכ mכlti-target sinagεstik rεguleshכn via di gεstrointestinal insulin aks, risεch dεn dכn rivεl komplimentari rol dεm fכ GLP-1, GIP, εn glukagon in mεtabolik rεguleshכn, we de gi wan tiori fכwndeshכn fכ divεlכp mכlti-rεsεptor agonist dεm.

Bil pan di prεviכs dual-target dכg divεlכpmεnt εkspiriεns, risεchכr dεn disayn εn optimiz Retatrutid bays pan di strכkchכral kכntribyushכn εn signal mεkanism dεm fכ dεn tripl rεsεpכta dεm ya. bay we i de aktibכt GLP-1R, GIPR, εn GCGR wan tεm, i de ajɔst mכr pכtεnt glycemic kכntrכl εn weit rεdukshכn.

Wetin na di mɛkanism fɔ akshɔn fɔ Retatrutid?

Risɛptɔ Agonism

rεtatrutid de fכnshכn lεk tripl rεsεpכta agonist we de tכk bכt GLP-1, GCGR, εn GIP rεsεpכta dεm ^[1]..

GLP-1 rεsεpכta agonism: GLP-1 na inkrεtin כmon we intestinal L sεl dεm de sekret. we i de biεn di GLP-1 rεsεpכta dεm, Retatrutid de protεkt insulin sekreshכn insay wan we we dipεnd pan glukכs-kכnsantreshכn. di tεm we di haypa glycemia de, Retatrutid de biεn di GLP-1 rεsεpכta dεm, we de aktibכt di dכwnstrim signal path dεm we de mek di pankrεas β-sεl dεm fכ sekret insulin εn lכs di blכd glukכs lεvεl. i de inhibit glukagon sekreshכn bak εn i de ridyus di hεpatik glukכs autput, we de mek di bכdi glukכs stebul mכr. GLP-1 rεsεpכta agonism de delay di gεstrik εmpti bak, i de mek di satiety bכku, εn i de ridyus di it we yu de it, we de εp fכ mεnεj di wet ^[2]..

GCGR rεsεpכta agonism: Glucagon tכpikכl de akt di tεm we di haypoglycemia de fכ εlevεt di bכdi glukכs lεvεl. Retatrutid in agonist akshכn pan GCGR na komplεks. insay adipose tisu, i de promuot lipolysis εn i de inkrεs fεt asid כksidεshכn, we de mek di εnεji spεndεshכn bכku. insay di liva, mכdarεt GCGR agonism kin rεgεl prכsεs dεm lεk gluconeogenesis, we de optimiz di hεpatik mεtabolik fכnshכn. dis de mek di gluconeogenesis we pasmak nכ de mek i gεt haypa glycemia we i de mεnten di bכdi glukכs stεbiliti fכ mit di εnεji we di bכdi nid ^{[1] .}.

GIP rεsεpכta agonism: GIP, we na כda inkrεtin כmon, na di K sεl dεm we de na di duodenum εn di jejunum de kכmכt afta dεn it. di GIP rεsεpכta agonism fכ retatrutid de εnhans insulin sekreshכn, we de sinagεj wit GLP-1 fכ impruv glukכs rεguleshכn. di kכnvεshכn, GIP rεsεpכta aktibכshכn kin infכlכw lipid mεtabolism εn εnεji bεlε. di risεch we Brzozowska P du sho se GIP de protεkt glukכs כptek εn lipid sεntesis insay adiposyt dεm. כltu, כnda Retatrutid in inflכεns, GIP signal de mכdulet fכ optimiz enεji yutilizeshכn pas fכ כnli promuot fεt stכrej, we de εp wet mεnejmεnt ^[1]..

Figure 1 di mεkanism dεm we Retatrutid de du ^[3]..

Komprεhεnsiv Rεgulεshכn כf Mεtabolik Prכsεs dεm

εnεji mεtabolism rεgulεshכn: bay we i de aktibכt di tri rεsεpכta dεm we wi bin dכn mεnshכn, Retatrutid de kכmprεhεnsiv rεgulεshכn εnεji mεtabolism. i de protεkt lipolysis, inkrεs fεt asid εntri insay maytochכndria fכ β-oksidashכn εn εnhans εnεji εkspεndishכn. i de ridyus di lipojenεsis bay we i de inhεbit fεt asid we de tek fεt asid εn triglisεrayd sεntesis insay adiposyt dεm, we de altεr di bכdi in enεji stכrej εn εkspεndishכn bεlε fכ mek i izi fכ lכs di wet. insay rilevεnt animal stכdi dεm εn klinik trial dεm we Jastreboff AM, Retatrutid administreshכn inkrεs εnεji εkspεndishכn rεt εn prכgrεsiv rεdכks bכdi fεt kכntεnt pan fat sכbjεkt dεm ^[4]..

Glukose Mεtabolism Rεgulεshכn: Retatrutid de mכdulet bכdi glukכs tru mכltipכl path dεm. biכn fכ stimulat insulin sekreshכn via GLP-1 εn GIP rεsεpכta aktibכshכn, i de infכlכw di hεpatik glukכs mεtabolism bay we i de rεgεl GCGR. i de sכpres di hεpatik glukonכjεnεsis we pasmak, i de ridyus di glukכs autput, εn di sem tεm i de εnhans di pεrifεral tisu glukכs כptek εn yutilizeshכn, we de mek i de mεnten di nכmal bכdi glukכs lεvεl. Dis na impɔtant tin fɔ di wan dɛn we fat pasmak we gɛt tayp 2 dayabitis, i kin kɔntrol di glukɔs na dɛn blɔd fayn fayn wan ɛn i kin mek dɛn gɛt mɔ dayabitis ^{[2] .}.

Liva Mεtabolik Rεgulεshכn: insay di liva, Retatrutid nכ de כnli mכdulet glukכs mεtabolism bכt i de infכlכw lipid mεtabolism bak. i de ridyus di hεpatik triglisεrayd sεntez εn akyumyuleshכn, i de impruv di hεpatik stεatosis, εn i de hכl pכtεnshal tεrapi valyu fכ nכn-alkohol fεt liva sik (NAFLD). insay klinik trial dεm we involv patisipan dεm wit mεtabolik disfכnkshכn-asכsiet fεt liva sik (MDAFLD), Retatrutid sכmtεm rεdכks hεpatik fεt kכntεnt, we sho in pכsitiv rεgεdyushכn ifekt pan hεpatik mεtabolism ^[5]..

 Efεkt dεm pan di Gεstrointestinal Fכnshכn

rεtatrutid de dilay di gεstrik εmpti bay we i de aktibכt GLP-1 rεsεpכta dεm. we yu ɛmti di bɛlɛ sloslo de mek di it we yu de it lɔng na di bɛlɛ, i de mek yu satisfay ɛn i de ridyus di it we yu de it afta dat. di sem tεm, i kin infכlכw di gכt כmon sekreshכn εn intestinal mכtiliti, fכ rεgεl di gεstrointestinal digεstεshכn εn di nyutriεnt absכpshכn prכsεs dεm, we de kכmprεhεnsiv afekt di enεji intake εn di bכdi wet ^[2]..

wetin na di sinagεstik mεkanism bitwin Retatrutid in agonistik ifekt dεm pan GLP-1, GCGR, εn GIP rεsεpכta dεm?

Sinajɛ in Ɛnaji Mɛtabolism Rɛgyuleshɔn

inkrεs εnεji εkspεndishכn: aktibכshכn fכ GCGR de protεkt glycogenolysis εn gluconeogenesis fכ εlevεt di bכdi glukכs lεvεl. i de εnhans di εnεji εkspεndishכn bak bay we i de inkrεs di lipid mεtabolism εn sכpres di it intake tru sεntri satiety. GLP-1R agonist dεm de mek insulin sekreshכn εn de εksyεrt kכdכprotεktiv εn nyuroprotεktiv ifekt dεm, we dεn de ridyus εnεji we dεn de tek bay we dεn de delay di gεstrik εmpti εn sכpres di apεtit. pan tap we di GIPR aktibכshכn insay adipos tisu de protεkt di lipid akyumyuleshכn, in sεntri aktibכshכn de ridyus di it we i de it εn i de mek di wet gεn sכmtεm. rεtatrutid de tכk to dεn tri rεsεpכta dεm ya wan tεm, we de establish nyu ikwilεbri bitwin di enεji intake εn εkspεndishכn. Dis kin mek yu nɔ gɛt bɔku ɛnaji, ɛn dis kin mek i izi fɔ lɛ yu lɔs yu wet.

rεgulεt lipid mεtabolism: GCGR agonism de εnhans lipid mεtabolism, we GIPR aktibכshכn insay adipos tisu de infכlכw lipid mεtabolism bak. GLP-1R agonist dεm kin indaykt afekt lipid mεtabolism tru mεkanism dεm lεk fכ impruv insulin sεnsitiviti. di sinagεstik akshכn dεm de bεtε rεgεl fεt sεntesis, brεk dכwn, εn transpכt, we de ridyus fεt akyumyuleshכn εn impruv di bכdi fεt distribushכn. fכ egzampl, stכdi dεm pan pipul dεm we fat sho se afta dεn yuz Retatrutid fכ sכm tεm, di bכdi fεt pasεnshכn dכn dכn εn di lipid profayl dεm impruv to sכm mak, we sho se in sinagεstik ifekt dεm fכ rεgεl di fεt mεtabolism ^[6]..

Sinerjistik Efεkt dεm na Glukoz Rεgulεshכn

εnhans Insulin Sekreshכn: GLP-1R agonist dεm de lכs bכdi glukכs bay we dεn de biεn to GLP-1 rεsεpכta dεm εn protεkt insulin sekreshכn. GIP semweso de mek di pankrεas β-sεl dεm fכ prodyuz insulin sekreshכn ifekt dεm we sכm kayn we lεk di wan dεm we dεn indyuz bay di it we dεn de it. rεtatrutid we de aktibכt GLP-1R εn GIPR wan tεm, de bכku bכku wan εnhans insulin sekreshכn, we de mek di blכd glukכs lεvεl dכn mכr ifektiv wan. pan ɔl we GCGR kin gɛt fɔ du wit ɛlevɛt blɔd glukɔs, in ifɛkt dɛn—lɛk fɔ mek dɛn spɛnd ɛnaji—kin indaykt wan kɔntribyut to glukɔs stebiliti we i de akt sinajɛstik wit riseptɔ dɛn lɛk GLP-1R. pan tap dat, di kכmbayn yus fכ GLP-1 εn GCGR de sεlektivli kכntrכl di haypa glycemic risk we GCGR de indyuz, we de mek i ebul fכ mכr prεsis εn ifektiv glukכs rεguleshכn.

rεgεlεt Glukoz Homכstasis: di sinagεstik aktibכshכn fכ dεn tri rεsεpכta dεm ya de εkstendi pas mεri insulin sekreshכn fכ inkכmpas kכmprεhεnsiv glukכs homכstasis rεguleshכn. bay we i de infכlכw di glukכs we de tek, yutilizeshכn, εn stכrej akraos mכltipכl tisu dεm we inklud di liva, mכsul, εn adipos, Retatrutid de mεnten di blכd glukכs insay wan rεlatεvli stebul rεnj, we de mek i nכ de fכm bכku bכku wan. Insay wan stכdi we Nicholls S bin du we involv tayp 2 dayabεtis pasεnshכn dεm, Retatrutid administreshכn rεsult in signifyant rεdukshכn pan glycated hεmoglobin lεvεl, we sho in pכsitiv impak pan lכng tεm glycemic kכntrכl εn sho di sinagεstik ifekt dεm fכ di tri rεsεpכta dεm fכ rεgεl glukכs homכstasis ^[6]..

Sinerjistik Aktivεshכn כf Signal Transdukshכn Pathways

kכmכn Signal Pathway Aktibכshכn: GLP-1R, GCGR, εn GIPR fכs signal tru G (Gαs) protin dεm. we Retatrutid de akt pan dεn tri rεsεpכta dεm ya, i de kכnvεrj fכ aktibכt shered dכwnstrכm path dεm lεk di cAMP-PKA path. dis shered path aktibכshכn de εnhans signal transdyushכn efyushכn εn pכtεns, amplify rεgεdyushכn ifekt dεm pan sεlyul mεtabolism εn fysiolojikal fכnshכn dεm.

kכdכnayt difrεn path dεm: we dεn de sheb kכmכn path dεm, εvri rεsεpכta de aktibכt yכnik signal nεtwכk dεm bak. rεtatrutid de mכdulet dεn difrεnt path dεm ya sinagεstik wan di tεm we rεsεpכta aktibכshכn de, we de mek i ebul fכ kכdכnayt mεtabolik rεguleshכn.

Sinerjistik Rεgulεshכn fכ di Gεstrointestinal Fכnshכn

Influεns Gastrointestinal Hכmon Sekreshכn: GLP-1R agonist dεm de stimulat GLP-1 sekreshכn, we GIPR agonist dεm de rεgεl GIP rilis. dis gεstrointestinal כmon dεm de ple imכtant rol fכ mכdulet di gεstrointestinal mכtiliti, digεsshכn, εn absכpshכn. bay we i de aktibכt di tu risεptor dεm wan tεm, Retatrutid de gi mכr kכmprεhεnsiv rεguleshכn fכ di gεstrointestinal hכmon sekreshכn, we de infכlכ di gεstrointestinal fכnshכn. i kin ridyus di rεpid nyutriεnt absכpshכn bay we i de mכdulet di gastric εmpti rεt εn intestinal mכtiliti, we de εp fכ kכntrכl di wet εn di glukכs na di bכdi.

impruv di Gastrointestinal Mεtabolik Envayroment: bay we i de rεgεl di gεstrointestinal hכmon sekreshכn, Retatrutid de εnhans di mεtabolik envayroment insay di gεstrointestinal trakt bak. i de mek di gכt εn mεtabolism fכ di bεnεfit gכt baktri dεm εn i de mכdulet di intestinal barεri fכnshכn. dis chenj dεm kin infכlכ di bכdi in כvala mεtabolik stet mכr. we dεn de wok sinagεstik wit ifekt dεm pan εnεji mεtabolism εn bכdi glukכs rεguleshכn, dεn mεkanism dεm ya kכlכktivli kכntribyut to di tεrapi ifekt dεm εgεst fכ fat εn rilat mεtabolik dizכrd dεm.

Wetin na di aplikeshɔn dɛn fɔ Retatrutid?

Tritmɛnt fɔ Fat pasmak

Sigifikant Weight Loss Effects: Bɔku klinik trial dɛn sho se Retatrutid de wok fayn fɔ trit pɔsin we fat pasmak. Insay wan Faz 2 dɛbul-blaynd, randomiz, plesibo-kɔntrol trial we Jastreboff AM bin du we involv 338 big pipul dɛn, di patisipan dɛn bin gɛt Retatrutid ɛvri wik pan difrɛn doz ɔ plasɛbo fɔ 48 wik. Rizult sho se na wik 24, di 1mg grup ajɔst wan avrej wet lɔs we na 7.2%, di 4mg kɔmbayn grup lɔs 12.9%, di 8mg kɔmbayn grup lɔs 17.3%, ɛn di 12mg grup lɔs 17.5%, we di plasɛbo grup lɔs 1.6% nɔmɔ. Bay wik 48, di 1mg grup bin ajɔst wan avrej wet lɔs we na 8.7%, di 4mg kɔmbayn grup lɔs 17.1%, di 8mg kɔmbayn grup lɔs 22.8%, di 12mg grup lɔs 24.2%, ɛn di plasɛbo grup lɔs 2.1%. Na di patisipan dɛm we bin gɛt 4mg, 8mg, ɛn 12mg Retatrutid, 92%, 100%, ɛn 100% bin ajɔst 5% ɔ mɔ wet lɔs, rispɛktvɔli. 75%, 91%, ɛn 93% bin ajɔst to 10% ɔ pas dat fɔ lɔs dɛn wet. ɛn 60%, 75%, ɛn 83% bin ajɔst 15% ɔ mɔ wet lɔs, kɔmpia to 27%, 9%, ɛn 2% na di plasɛbo grup. Dɛn data ya de sho klia wan se Retatrutid de wok fayn fɔ ridyus di wet fɔ di wan dɛn we fat ^{[4] .}.

Tayp 2 Dayabitis Tritmɛnt

Glycemic Control Efficacy: Stɔdi dɛn we Lopez DC ɛn ɔda pipul dɛn du. indiket se Retatrutid de impכkt glycemic kכntrכl fayn fayn wan pan tayp 2 dayabεtis pasεnshכn dεm. Insay wan trayal we involv 353 patisipan dɛm, Retatrutid ridyus glycated hemoglobin (HbA1c) bay 1.64% kɔmpia to plasɛbo. Dis de sho se Retatrutid de wok fayn fɔ mek di blɔd glukɔs lɛvɛl dɔŋ pan tayp 2 dayabitis, ɛn dis de ɛp fɔ mek di klinik autkam dɛn bɛtɛ ^[7]..

kכmbayn mεkanism advantej: rεtatrutid de akt pan mכltipכl rεsεpכta dεm, we de gi wan yכnik advantej oba singl-rεsεpכta agonist dεm tru in kכmbayn agonist mεkanism. i nכ de כnli lכs di glukכs na di bכdi bay we i de mek insulin sekreshכn bכt i de εnhans insulin sεnsitiviti, we de mek di bכdi sεl dεm ebul fכ yuz insulin mכr ifektiv fכ kכmprεhεnsiv glycemic kכntrכl. di ifekt dεm we i de du we de ridyus di wet de impruv mεtabolik stetכs mכr pan tayp 2 dayabεtis pasεnshכn dεm, biכs fכ fat na big risk fכ di kכndyushכn εn we di wet lכs de mek i izi fכ mεnεj di glukכs na di bכdi ^[5]..

Tritmɛnt fɔ Nɔn-Alkohol Fat Liva Sik

Ridyus Liva Fεt Kכntεnt: Retatrutid sho di abiliti fכ ridyus liva fεt kכntεnt pan pasεnshכn dεm we gεt mεtabolik disfכnkshכn-asכsiet fεt liva sik (MDAFLD) εn liva fεt kכntεnt ≥10%. Insay wan randomized, double-blind, placebo-controlled trial, 98 patisipan dɛn bin randomly asaynd fɔ gɛt ɛvri wik sabkyutan injɛkshɔn fɔ Retatrutid (1mg, 4mg, 8mg, ɔ 12mg) ɔ plasɛbo fɔ 48 wik. Rizult sho se na wik 24, di min chenj in hεpatik fεt kכntεnt rεlatεv to di beslayn na -42.9% in di 1mg grup, -57.0% in di 4mg grup, -81.4% in di 8mg grup, εn -82.4% in di 12mg grup, kכmpεr to +0.3% in di plasεbo grup. dis tin dεm we dεn fכnshכn sho se Retatrutid de ridyus di hεpatik fεt kכntεnt bכku, we de sho pכtεnshal tεrapi valyu fכ nכn-alkohol fεt liva sik ^[8]..

fכ impruv di εpatik mεtabolik fכnshכn: rεtatrutid de εnhans di liva mεtabolik fכnshכn bay we i de rεgεl εnεji εn lipid mεtabolism. i de promuot di oksidashכn εn brεk dכwn fכ di hεpatik fεt dεm, i de ridyus di fεt we de kכmכt na di liva, i de mכdulet di inflammatory rispכns dεm εn di oksidativ strεs lεvεl dεm insay di liva, εn i de εksyεrt wan sכm inhibitory ifekt pan di prכgreshכn fכ NAFLD, we de protεkt di sikman dεm in liva hεlth.

Dɔn

as tripl rεsεpכta agonist fכ GLP-1R/GIPR/GCGR, Retatrutid de εksyεrt mεtabolik rεgεdyushכn ifekt dεm tru wan mכlti-tכgεt sinagεstik mεkanism. di ifekt dεm we i gεt de kכmכp fכ aktibכt GLP-1R fכ sכpres apεtit εn delay gastric εmpty, we de ridyus di enεji intake; aktibכt GIPR fכ εnhans insulin sekreshכn εn impruv insulin sεnsitiviti; εn fכ aktibכt GCGR fכ protεkt lipolysis εn εnεji εkspεndishכn we i de rεgεl di hεpatik glukכs εn lipid mεtabolism fכ ridyus fεt akyumyuleshכn. dis tripl sinaji de achy komprεhεnsiv ifekt dεm we inklud pכtεnt glycemic kכntrכl, signifyant weit lכs, εn impruv lipid εn hεpatik fεt mεtabolism. I kor valyu de pan ɔbisiti tritmɛnt, we de ajɔst di doz-dipɛndent fɔ ridyus di wet wit maksimal 48 wik lɔs we na 24.2%. Fɔ tayp 2 dayabitis, i kin rili lɔs di glycated hemoglobin ɛn i kin mek di glycemic homeostasis bɛtɛ. insay mεtabolik disfכnkshכn-asכsiet fεt liva sik, i de ridyus di hεpatik fεt kכntεnt bכku bכku wan, we de sho pכtεnt efikכs akraos mכltipכl mεtabolik dizכrd dεm.

Bɔt di pɔsin we rayt di buk

Di tin dɛm we wi dɔn tɔk bɔt ɔp na ɔl di risach, ɛdit ɛn kɔmpilayt na Cocer Peptides.

Sayɛns Jɔnal Author

Arun J. Sanyal na ɛpatɔlɔjis ɛn risachman we spɛshal pan liva sik dɛm, mɔ di nɔ-alkohol fat liva sik (NAFLD) ɛn nɔ-alkohol stiatohepatitis (NASH). I gɛt fɔ du wit di Virginia Commonwealth University School of Medicine, usay i dɔn bi fakulti mɛmba frɔm 1989. Sanyal dɔn rayt lɛk 1,000 buk dɛn na big big jɔnal dɛn lɛk Cell Metabolism, Nature Medicine, The New England Journal of Medicine, ɛn The Lancet. Dɛn dɔn tɔk bɔt in wok pas 104,000 tɛm, we sho se i gɛt bɔku impak pan di fild fɔ ɛpatɔlɔji. I dɔn kɔntinyu fɔ gɛt mɔni frɔm di Nashɔnal Instityut fɔ Wɛlbɔdi biznɛs frɔm 1995 ɛn na di prinsipal invɛstigatɔ fɔ 4 aktif NIH grant dɛn. Dɛn dɔn no Sanyal bak fɔ in lidaship pan klinik risach ɛn in kɔntribyushɔn fɔ divɛlɔp tritmɛnt strateji fɔ liva sik. Arun J. Sanyal de na di list insay di rɛfrɛns fɔ saytayshɔn [5].

▎ Saytayshɔn dɛn we gɛt fɔ du wit dis

[1] Brzozowska P, Frańczuk A, Nowinska B, Makłowicz A, Palacz KA, Lenartowicz I. Retatrutid - rivɔlɔshɔnari we dɛn jɔs dɔn divɛlɔp GLP agonist - litrɛcha rivyu. Kwaliti in Spɔt 2024. Di s://api.semanticscholar.org/KɔpɔsID:271031379. Di wan dɛn we de stɔdi bɔt di Baybul.

[2] Dɔgrɛl S. A. Retatrutid we de sho prɔmis pan fat (ɛn tayp 2 dayabitis). Ekspɛkt Opinion Pan Investigeshɔn Drugs 2023; 32(11): 997-1001.DOI: 10.1080/13543784.2023.2283020. Di wan dɛn we de stɔdi bɔt di Baybul.

[3] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutid—A Gem Chenj in Ɔbisiti Famakotɛrapi. Bayomɔlikul dɛn 2025; 15(6).DOI: 10.3390/biɔm15060796.

[4] Jastreboff A. M., Kaplan L. M., Frías J. P., ɛn ɔda pipul dɛn. Tripul-Hכmon-Rεsεptor Agonist Rεtatrutid fכ Obesiti - Wan Faz 2 Trayal. Nyu Ingland Jɔnal fɔ Mɛdisin 2023; 389(6): 514-526. DOI: 10.1056/NEJMoa2301972. Di wan dɛn we de wok fɔ di kɔmni.

[5] Sanyal A. J., Kaplan L. M., Frias J. P., ɛn ɔda pipul dɛn. Tripul hכmon rεsεptכr agonist rεtatrutide fכ mεtabolik disfכnkshכn-asכsiet stεatotik liva sik: wan randomizεd fεz 2a trayal. Nature Mɛdisin 2024; 30: 2037-2048, ɛn di ɔda wan dɛn. https://api.semanticscholar.org/CorpusID:270378167. Di wan dɛn we de stɔdi bɔt di Baybul.

[6] Nicholls S, Pirro V, Lin Y, ɛn ɔda pipul dɛn. tripl-hכmon rεsεptכr agonist rεtatrutide de impruv di lipoprotein εn apolipoprotein profayl dεm bכku bכku wan pan patisipan dεm we fat כ ova wet. Yuropian At Jɔnal 2024; 45(Saplimɛnt_1): ɛhae666-ɛɛ1501.DOI: 10.1093/ɛurhatj/ɛɛ666.1501.

[7] Lopez D. C., Pajimna J. T., Milan M. D., ɛn ɔda pipul dɛn. 7792 Efficacy of Retatrutid fכ Weight Ridukshכn εn In Cardiometabolic Efεkt dεm bitwin Adult dεm: Wan Sistεmatik Rivyu εn Mεta-Analysis. J ɔ rnal ɔ f di Ɛndokrin Sɔsayti 2024; 8(Saplimɛnt_1): bvae163-bvae749.DOI: 10.1210/jendso/bvae163.749.

[8] Naeem M, Imran L, Banatwala U. Unleashing di pawa fɔ retatrutide: Wan pɔsibul triɔmp oba ɔbisiti ɛn ɔvaweit: Wan kɔrɛspɔndɛns. Ɛlth Sayns Ripɔt dɛn 2024; 7(2): e1864.DOI: 10.1002/hsr2.1864.

ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL DI INFƆMƐSHƆN DISƐMƐNƐSHƆN ƐN FƆ EDYUKESHƆN.  

Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.